Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias R Benz

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 28, 2012
Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PETH Christian Rischke, Matthias R Benz, Damian Wild, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2021
18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal AdenocarcinomaMatthias R Benz, Wesley R Armstrong, Francesco Ceci, et al.
Cancer|December 13, 2012
(18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcomaAkram Al-Ibraheem, Andreas K Buck, Matthias R Benz, et al.
Radiology|July 11, 2023
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate CancerAndrei Gafita, Loïc Djaileb, Isabel Rauscher, et al.
Cancer Discovery|December 12, 2012
Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatmentDaniel Braas, Ethan Ahler, Brenna Tam, et al.
Sarcoma|April 24, 2010
FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone SarcomasMatthias R Benz, Johannes Czernin, William D Tap, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2012
18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapyKen Herrmann, Matthias R Benz, Johannes Czernin, et al.
Scientific Reports|October 17, 2024
Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapyJohn Nikitas, Andrei Gafita, Matthias R Benz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 2021
<sup>18</sup>F-FLT PET/CT as a Prognostic Imaging Biomarker of Disease-Specific Survival in Patients with Primary Soft-Tissue SarcomaJoseph G Crompton, Wesley R Armstrong, Mark A Eckardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomasMatthias R Benz, Johannes Czernin, Martin S Allen-Auerbach, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 28, 2012
Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PETH Christian Rischke, Matthias R Benz, Damian Wild, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2021
18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal AdenocarcinomaMatthias R Benz, Wesley R Armstrong, Francesco Ceci, et al.
Cancer|December 13, 2012
(18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcomaAkram Al-Ibraheem, Andreas K Buck, Matthias R Benz, et al.
Radiology|July 11, 2023
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate CancerAndrei Gafita, Loïc Djaileb, Isabel Rauscher, et al.
Cancer Discovery|December 12, 2012
Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatmentDaniel Braas, Ethan Ahler, Brenna Tam, et al.
Sarcoma|April 24, 2010
FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone SarcomasMatthias R Benz, Johannes Czernin, William D Tap, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2012
18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapyKen Herrmann, Matthias R Benz, Johannes Czernin, et al.
Scientific Reports|October 17, 2024
Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapyJohn Nikitas, Andrei Gafita, Matthias R Benz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 2021
<sup>18</sup>F-FLT PET/CT as a Prognostic Imaging Biomarker of Disease-Specific Survival in Patients with Primary Soft-Tissue SarcomaJoseph G Crompton, Wesley R Armstrong, Mark A Eckardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomasMatthias R Benz, Johannes Czernin, Martin S Allen-Auerbach, et al.
Pageof 6